Strides acquires generic brands from Sandoz to boost Africa business

The initial consideration for the transaction is US$ 12 million

Johnson & Johnson reports promising early results for targeted bladder cancer therapy

FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors

EU clears AstraZeneca’s Imfinzi combo for early gastric & GEJ cancers

AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible

BioDuro and Cenra API Solutions forge global API manufacturing joint venture in Taiwan

The Taipei facility boasts 10 GMP API production lines, with a total reactor volume exceeding 350,000 liters

GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group

Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk

Aptar Pharma teams up with COVIRIX Medical to explore next-generation antiviral inhaler

COVIRIX Medical says its broad-spectrum antiviral portfolio has already shown positive virology results against key pandemic threats

First patient dosed in trial of novel drug targeting limb-threatening artery disease

The trial will enroll up to 42 patients in Finland across four cohorts

GenScript launches first European mRNA production hub in Delft, bolstering EU biotech leadership

Abbott study shows continuous glucose monitoring outperforms fingersticks in Type 2 diabetes

This study demonstrates the power of real-time glucose information for people with Type 2 diabetes treated with basal insulin

QIAGEN bags FDA nod for full GI testing on QIAstat-Dx Rise system

The approval means US laboratories can now run both respiratory and gastrointestinal panels on the high-throughput QIAstat-Dx Rise